Learn more about INPLASYⓇ
Our Mission
"To provide researchers worldwide with the opportunity to register and share evidence synthesis protocols rapidly and without barriers. INPLASY helps reduce duplication of research efforts, minimizes reporting bias, and promotes transparency and integrity in scientific research."
Our Vision
"To deliver an innovative global platform for the registration of evidence synthesis protocols."
Our History
INPLASY is an international platform for the registration of evidence synthesis protocols, including systematic reviews and meta-analyses, officially launched in March 2020. Protocol registrations increased rapidly during the first 12 months, reaching more than 1,400 records submitted by authors from 25 countries. As of 28 February 2026, INPLASY has more than 9,000 registered users, over 780,000 website views from 195 countries, and more than 8,800 registered protocols submitted by authors from 94 countries worldwide.
Protocols from 94 countries: Angola, Australia, Austria, Bahrain, Bangladesh, Belgium, Bolivia, Brazil, Bulgaria, Burkina Faso, Canada, Chile, China, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Ethiopia, Finland, France, Gambia, Germany, Ghana, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Macau, Malawi, Malaysia, Mexico, Morocco, Mozambique, Myanmar, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Palestine, Peru, Philippines, Poland, Portugal, Qatar, Republic of Korea, Romania, Russia, Saudi Arabia, Senegal, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Sudan, Sweden, Switzerland, Syria, Taiwan, Tanzania, Thailand, Tunisia, Turkey, Uganda, United Arab Emirates, United Kingdom, United States of America, Uzbekistan, Vietnam, Yemen.
More than 790K website views from 195 countries
Updated on 28 February 2026
It is essential to identify evidence syntheses that already exist and ongoing systematic reviews before starting a new project to avoid duplication effort. Although registration in PROSPERO is considered the standard, it is not possible for a single platform to be able to register all systematic review protocols developed around the world. Solla et al. showed that even PROSPERO registration does not prevent double review registration on the same topic. Thus, the authors are responsible for searching for ongoing systematic reviews in the pipeline before submitting their protocols.
1 – The international platform of registered systematic review and meta-analysis protocols (INPLASY) at 3 years: an analysis of 4,658 registered protocols on inplasy.com, platform features, and website statistics. Canellas et al. Front. Res. Metr. Anal., 31 July 2023 https://doi.org/10.3389/frma.2023.1135853
2 – Solla F, Bertoncelli CM, Rampal V. Does the PROSPERO registration prevent double review on the same topic? BMJ Evid Based Med. 2020 Feb 13:bmjebm-2020-111361. doi: 10.1136/bmjebm-2020-111361. PMID: 32054725.
The COVID-END resources and tools for researchers considering and conducting COVID-19 evidence syntheses were last updated by McMaster University on 17 June 2020. Before starting a new project, this working group indicates that researchers should seek ongoing reviews not only in PROSPERO, but in INPLASY, National Collaborating Centre, Centre for Evidence Based Medicine, and VA Evidence Synthesis Program.
3 – COVID-END – COVID-19 Evidence Network to support Decision-making – Resources for researchers – Identify ongoing reviews/ avoid duplication effort; 2.2.2 (Available: https://www.mcmasterforum.org/docs/default-source/covidend/covid-end_researchers.pdf?sfvrsn=437e56d5_4).
Our Values
We promote transparency and efficiency by publishing protocols within 48 hours after submission through a streamlined administrative check, reducing research waste and duplication.
